**Supplemental figure 5:** Molecular characterization of exosomes derived from TPC1, FTC-133, and 8505C using Western blot analysis. (A) Purified exosomes secreted by three thyroid cancer cell lines were analyzed by immunoblotting for the presence of the exosome marker CD63. (B) CD63 expression in exosomes secreted by equal amount of thyroid cancer cells treated with Brefeldin A, or vehicle (Methanol) (12 hours for TPC1 and FTC-133 and 16 hours for 8505C). (C) Expression of miR-145 was decreased by the treatment of thyroid cancer cells with GW4869 (1 μM) during 48h. (D) Purified exosomes secreted by equal amount of cells treated with GW4869 or vehicle (DMSO) during 48 hours were analyzed by Western blot for CD63 expression. (*,p<0.05; **,p<0.01, ***p<0.001).